The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMast Energy. Regulatory News (MAST)

Share Price Information for Mast Energy. (MAST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.325
Bid: 0.30
Ask: 0.35
Change: 0.00 (0.00%)
Spread: 0.05 (16.667%)
Open: 0.325
High: 0.325
Low: 0.325
Prev. Close: 0.325
MAST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

11 Apr 2024 07:00

RNS Number : 1094K
Mast Energy Developments PLC
11 April 2024
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

('MED' or 'the Company')

 

Dated: 11 April 2024

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

Business Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, is pleased to announce an update regarding business operational matters.

 

HIGHLIGHTS

 

· The initial first phase work programme at MED's Pyebridge 9MW flexible power generation asset ("Pyebridge") successfully completed ahead of schedule, with the site now officially back into operation.

 

· Initial pre-construction work completed at MED's 7.5MW Hindlip Lane flexible power generation project ("Hindlip"), and Certificate of Lawful Commencement granted.

 

FURTHER INFORMATION

 

Pyebridge

 

Further to the Company's previous announcement dated 28 February 2024, the MED management team successfully completed the initial work programme ahead of schedule at its Pyebridge 9MW flexible power generation asset ("Pyebridge"), with the site now officially back into operation.

 

Resultingly, MED was able to schedule and perform the minimum 3x separate generation runs ahead of schedule to meet its Satisfactory Performance Days ("SPD") requirements that are due by the end of April 2024 under its existing T-1 Capacity Market contract (the "CM Contract"). It is expected that Pyebridge will pass its next SPD test, and retain the CM Contract's associated annual gross profit margin income of c. £308,000 which is paid and received monthly in arrears.

 

Additionally, as previously announced the Pyebridge site has secured further Capacity Market contracts to ensure minimum annual gross profit margin income as follows:

 

· T-1 2024/2025 CM contract - c. £183,000 gross profit margin income;

· T-4 2026/2027 CM contract - c. £312,000 gross profit margin income; and

· T-4 2027/2028 CM contract - c. £322,000 gross profit margin income.

 

MED expects to bid for and secure an additional T-1 Capacity Market contract for the 2025/2026 delivery year in the next upcoming Capacity Market auction, thereby ensuring uninterrupted guaranteed income until 2028. The Site's existing Capacity Market contracts are all fixed one-year contracts. MED expects to apply for the maximum 15-year term and capacity T-4 Capacity Market contract in due course.

 

The Pyebridge site's Capacity Market contracts' gross profit margin income payments are in addition to its electricity generation trading revenue generation via its PPA with Statkraft. The plan and intention is to add a minimum guaranteed gross profit margin income floor component to its PPA with Statkraft (the "PPA Floor"). The PPA Floor value is currently expected to be at around £50/kW/annum, subject to certain usual conditions such as assessment and agreement by Statkraft, which would equate to an additional minimum annual gross profit margin income of £405,000.

 

Both the above referred longer-term Capacity Market contract and the PPA Floor are expected to be implemented once the Pyebridge site's planned overhaul work programme as referred to below has been completed, in order to provide further enhanced and longer term minimum guaranteed gross profit margin income to the site.

 

Further, following the successful completion of the first phase of the work programme, the plan and intention is that the next larger second phase work programme (the "2nd Phase") will be initiated shortly. The 2nd Phase will be performed in separate consecutive tranches on each of the Pyebridge site's 3x gensets, and is expected to take around 6 to 8 weeks per genset.

The cost of the 2nd Phase will be funded under the new funding agreement as recently announced. The 2nd Phase will involve the following main improvements to the site and gensets, in order to get the site up to its full efficiency, revenue generation and profitability potential:

 

· Complete long-block and major parts replacements and full overhauls for each of the existing 3 x Jenbacher J620 engines.

· Replacement engine long-blocks will feature upgraded internal deflagration protection technology, which will significantly reduce the risk of potential damage due to engine backfires.

· The overhauls will ensure optimal overall generation efficiency, reduced operations- and maintenance costs and downtime, and optimal overall availability.

 

Hindlip and MED's other existing sites

 

Initial pre-construction work at Hindlip was successfully completed to satisfy planning consent requirements. As a result, the site's Certificate of Lawful Commencement has been granted.

 

The following MED sites, Hindlip (7.5MW), Bordesley (4.5MW) and Rochdale (4.5MW) are each construction-ready, with all required key cornerstones of a flexible generation site in place and in good standing, most notably fully specified EPC and O&M offers, planning consent, gas connection offer, grid connection offer and construction management plan. Subject to capex funding, these sites will immediately continue with the construction phase with an expected timeline to commercial operations date of around 12 months from receipt of funding, to go into production and revenue generation.

 

Project Capex Funding

 

As stated above, most of MED's sites under development are either ready for construction, or in early-stage construction, subject to securing project capex funding. In order to address this key next step in these projects' development lifecycle to get each project into production as quickly as possible, MED is currently in discussions with various potential debt and equity funders, including banking institutions that are interested to provide the necessary capex funding.

 

Pieter Krügel, MED CEO, commented"We are pleased to have successfully completed the first phase work programme at Pyebridge, and that the site is now back into operation. We are looking forward to initiating the next 2nd Phase work programme shortly, which when successfully completed will see the site operating and generating income at its full expected efficiency, availability and profitability potential. We will update the market with progress in due course."

 

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel

info@med.energy

Mast Energy

Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDVBLFFZZLXBBQ
Date   Source Headline
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
26th Apr 20247:00 amRNSBusiness Update
23rd Apr 20242:30 pmRNSHolding(s) in Company TR 1
11th Apr 20247:00 amRNSBusiness Update
7th Mar 20248:06 amRNSQ1 2024 Corporate Presentation
4th Mar 202410:45 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSFunding Partner, Agreement & Proventure Terminated
20th Feb 20241:00 pmRNSTR-1: Standard form notification of major holdings
5th Feb 20241:55 pmRNSTR-1: Standard form notification of major holdings
24th Jan 20243:45 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSMED Binding JVA Progress Update
2nd Jan 20247:00 amRNSMED Binding JVA Completion Update
22nd Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Dec 20237:00 amRNSDirector Loan & PDMR Share Sale
11th Dec 20237:52 amRNSMED Binding JVA Update
11th Dec 20237:00 amRNSMED Binding JVA Completion Update
5th Dec 20234:30 pmRNSHolding(s) in Company
1st Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Nov 20233:31 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSMED Binding JVA Interim Payment Update
26th Oct 202310:54 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn
20th Dec 20222:00 pmRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSPyebridge SPA Deferred Consideration Settlement
15th Dec 20222:00 pmRNSTR-1: Notification of major holdings
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSBordesley Update
17th Nov 20227:00 amRNSCorporate Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.